225 related articles for article (PubMed ID: 15504573)
1. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
Tsai SJ
Med Hypotheses; 2004; 63(6):1047-50. PubMed ID: 15504573
[TBL] [Abstract][Full Text] [Related]
2. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
Costentin J
Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
5. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole (Otsuka Pharmaceutical Co).
Ozdemir V; Fourie J; Ozdener F
Curr Opin Investig Drugs; 2002 Jan; 3(1):113-20. PubMed ID: 12054061
[TBL] [Abstract][Full Text] [Related]
7. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
Kim SW; Shin IS; Kim JM; Youn T; Yang SJ; Hwang MY; Yoon JS
Clin Neuropharmacol; 2009; 32(4):224-6. PubMed ID: 19644229
[TBL] [Abstract][Full Text] [Related]
8. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia: from dopamine to glutamate and back.
Carlsson ML; Carlsson A; Nilsson M
Curr Med Chem; 2004 Feb; 11(3):267-77. PubMed ID: 14965231
[TBL] [Abstract][Full Text] [Related]
10. Partial agonism and schizophrenia.
Bolonna AA; Kerwin RW
Br J Psychiatry; 2005 Jan; 186():7-10. PubMed ID: 15630117
[No Abstract] [Full Text] [Related]
11. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
Costentin J
Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
[TBL] [Abstract][Full Text] [Related]
12. Central dopaminergic mechanisms in schizophrenia.
Owen F; Crow TJ; Poulter M
Acta Psychiatr Belg; 1987; 87(5):552-65. PubMed ID: 2897760
[TBL] [Abstract][Full Text] [Related]
13. [Aripiprazole as "dopamine sensitivity stabilizer"].
Tadokoro S
Nihon Rinsho; 2013 Apr; 71(4):684-8. PubMed ID: 23678600
[TBL] [Abstract][Full Text] [Related]
14. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.
Yeh YW
Clin Neuropharmacol; 2011; 34(4):135-6. PubMed ID: 21768798
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
Hirose T; Kikuchi T
J Med Invest; 2005 Nov; 52 Suppl():284-90. PubMed ID: 16366516
[TBL] [Abstract][Full Text] [Related]
16. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being.
Liemburg E; Aleman A; Bous J; Hollander K; Knegtering H
Pharmacopsychiatry; 2011 May; 44(3):109-13. PubMed ID: 21432752
[TBL] [Abstract][Full Text] [Related]
17. Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?
Zajdel P; Partyka A; Marciniec K; Bojarski AJ; Pawlowski M; Wesolowska A
Future Med Chem; 2014 Jan; 6(1):57-75. PubMed ID: 24358948
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.
Kuo J; Hwu HG
Clin Neuropharmacol; 2008; 31(3):173-5. PubMed ID: 18520984
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D2 receptors as treatment targets in schizophrenia.
Seeman P
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
[TBL] [Abstract][Full Text] [Related]
20. [Disappearance of paroxysmal perceptual alteration by switching to aripiprazole in a schizophrenic patient].
Kondo M; Ikejiri Y; Hanatani T; Sumi N
Seishin Shinkeigaku Zasshi; 2010; 112(1):23-30. PubMed ID: 20184237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
